Recent corporate press releases and regulatory filings from NervGen Pharma highlight its second-quarter financial updates, confirming a strong cash position exceeding C$86 million following a successful public offering that fully funds operations through upcoming clinical readouts. Further announcements detail preparations for the Phase 3 RESTORE study screening schedule, upcoming patient-focused drug development meetings, and plans for an inaugural R&D Day dedicated to showcasing its neuroreparative pipeline.